Abstract:
HDT-AHCT is a standard potentially curative therapy for aggressive lymphomas. Despite improvements in supportive care, severe regimen-related toxicities (SRRT) are common and may limit use of HDT-AHCT. Frequently, SRRT involves the oral-gastrointestinal (oral/GI) tract as nausea, vomiting, diarrhea, and severe mucositis leading to high symptom burden, and increased risk for serious complications.
AB-205 is an experimental engineered-cell therapy designed to accelerate regeneration of organs and eliminate or reduce SRRT. AB-205 contains E-CEL® (allogeneic E4+ human umbilical vein endothelial) cells. Preclinical studies of E-CELs infused after conditioning have shown accelerated recovery of multiple organ functions.
Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR – Monday, February 8, 2021
Lihua E. Budde, MD, PhD1, Michael Scordo, MD2, Mehrdad Abedi, MD3, Carolyn Mulroney, MD4, Bita Fakhri, MD, MPH5, Attaphol Pawarode, MD, PhD6, MI, Bhagirathbhai Dholaria, M.B.B.S.7, Geoffrey Shouse, DO, PhD8, Edward Kavalerchik, MD9, Sanjay H. Aggarwal, MD9, Muzaffar H. Qazilbash, MD10, Paul Finnegan, MD9, and Sergio A. Giralt, MD2
1City of Hope National Medical Center, Duarte, CA, 2Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, 3Hematology/Oncology, UC Davis, Sacramento, CA, 4Blood and Marrow Transplantation, UCSD Moores Cancer Center, La Jolla, CA, 5Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, 6Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI, 7Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, 8Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, 9Angiocrine Bioscience, San Diego, CA, 10Stem Cell Transplantation & Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX,
Go to TCT Meeting – 2021